CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
NCT Number: NCT01602185
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity.
In clinical, after ketamine cure, clinicians have often difficulties to treat patients in order to maintain analgesia or suggest another treatment if analgesia induced by ketamine was not effective, which occurs in one quarter of patients. It will be very useful for monitoring of painful patients evaluate if memantine or dextromethorphan could be an effective therapeutic alternative in neuropathic pain treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Clermont-Ferrand, 63003, France
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity.
In clinical, after ketamine cure, clinicians have often difficulties to treat patients in order to maintain analgesia or suggest another treatment if analgesia induced by ketamine was not effective, which occurs in one quarter of patients. It will be very useful for monitoring of painful patients evaluate if memantine or dextromethorphan could be an effective therapeutic alternative in neuropathic pain treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
DN4, QCD, QDSA, PGIC questionnaires, HAD scale, Leed's sleep evaluation and SF36.
Exclusion criteria
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Time frame: at Day 30
Time frame: at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
Time frame: at day 30, at day 60 and at day 90
University Hospital, Clermont-Ferrand
Other
Antagonists NMDA in Relay to Ketamine in Neuropathic Pain
Acronym: NMDA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03848143
Nervous System Diseases, Neuralgia
Lexington, Kentucky, United States
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT05998369
Abdominal Pain, Autonomic Nervous System Diseases
Palo Alto, California, United States
View Trial DetailsNCT06568042
Distal Sensory Polyneuropathy, Nervous System Diseases
Chandler, Arizona, United States
View Trial Details